Featured Research

from universities, journals, and other organizations

Researchers identify a signaling pathway as possible target for cancer treatment

Date:
August 15, 2011
Source:
NYU Langone Medical Center / New York University School of Medicine
Summary:
In a new study, researchers have identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

Researchers have identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.
Credit: NYU School of Medicine

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

"We have known for a long time that blood vessels branch to give rise to new ones and that in some places of our bodies this branching occurs with a reproducible pattern. However, the mechanisms that ensure that new vessels sprout at specific locations had not been uncovered until now," said Jesús Torres-Vázquez, PhD, assistant professor of Developmental Genetics at the Skirball Institute of Biomolecular Medicine at NYU School of Medicine. "Our study illuminates the genetic basis behind the reproducible pattern of the vasculature and suggests ways in which the formation of new blood vessels could be modulated to treat certain cancers in the future."

Using the zebrafish embryo as a model system, researchers identified that Semaphorin-PlexinD1 signaling limits the formation of new blood vessels. This signaling pathway works by ensuring that blood vessels make the proper levels of soluble Flt1. Soluble Flt1 is an inhibitor of the Vascular Endothelial Growth Factor (VEGF) pathway, which promotes the growth of new blood vessels.

These findings have broad implications for human health, since changes in the level of soluble Flt1 are associated with cancer, vascular birth defects and pregnancy-related hypertension (preeclampsia).

According to researchers, the Semaphorin-PlexinD1 signaling pathway shows significant promise as a future therapeutic target for cancer treatment to slow the progression of diseases by controlling the blood vessel growth.

In addition, a related study by Dr. Torres-Vázquez illuminates how the development of the brain and its vasculature is coordinated providing greater understanding about why defects form in the brain's blood vessels and how the blood vessels of the brain form. These study findings were published in the July 2011 issue of Developmental Biology.


Story Source:

The above story is based on materials provided by NYU Langone Medical Center / New York University School of Medicine. Note: Materials may be edited for content and length.


Journal References:

  1. Tomasz Zygmunt, Carl Michael Gay, Jordan Blondelle, Manvendra K. Singh, Kathleen McCrone Flaherty, Paula Casey Means, Lukas Herwig, Alice Krudewig, Heinz-Georg Belting, Markus Affolter, Jonathan A. Epstein, Jesús Torres-Vázquez. Semaphorin-PlexinD1 Signaling Limits Angiogenic Potential via the VEGF Decoy Receptor sFlt1. Developmental Cell, 2011; 21 (2): 301-314 DOI: 10.1016/j.devcel.2011.06.033
  2. Florian Ulrich, Leung-Hang Ma, Robert G. Baker, Jesús Torres-Vázquez. Neurovascular development in the embryonic zebrafish hindbrain. Developmental Biology, 2011; 357 (1): 134 DOI: 10.1016/j.ydbio.2011.06.037

Cite This Page:

NYU Langone Medical Center / New York University School of Medicine. "Researchers identify a signaling pathway as possible target for cancer treatment." ScienceDaily. ScienceDaily, 15 August 2011. <www.sciencedaily.com/releases/2011/08/110815121343.htm>.
NYU Langone Medical Center / New York University School of Medicine. (2011, August 15). Researchers identify a signaling pathway as possible target for cancer treatment. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/08/110815121343.htm
NYU Langone Medical Center / New York University School of Medicine. "Researchers identify a signaling pathway as possible target for cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2011/08/110815121343.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins